Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]
News [3134]
Articles [127]
Editorials [3]
Conferences [119]
elearning [13]
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Continuous treatment versus fixed duration therapy: Using real-world evidence...
Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin
Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )
23 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
23 Sep 2019
Evaluating treatment options for acute myeloid leukaemia
Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA
Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Recent advances in smouldering and relapsed or refractory multiple myeloma
Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA
Recent advances in smouldering and relapsed or refractory multiple myeloma ( Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA )
26 Jul 2019
Use of platform studies for the evaluation of innovative combinations in solid...
Dr Elizabeth Pease - AstraZeneca, UK
Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies ( Dr Elizabeth Pease - AstraZeneca, UK )
10 Jul 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Chemotherapy-free strategies in treating leukaemia
Prof Robin Foa - University of Rome, Rome, Italy
Chemotherapy-free strategies in treating leukaemia ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation